-
Company Insights
Innovation and Patenting activity of Neoleukin Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Neoleukin Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Graft Versus Host Disease (GVHD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Drugs In Development, 2023’, provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Bone Marrow Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Bone Marrow Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Bone Marrow Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Interstitial Cystitis (Painful Bladder Syndrome) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Interstitial Cystitis Clinical Trials Overview The report provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) clinical trial scenario and top-line data relating to the clinical trials. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. Key Regions ·       North America ·       Asia-Pacific ·       Europe ·       ...
-
Company Profile
Neoleukin Therapeutics Inc – Company Profile
Neoleukin Therapeutics Inc (Neoleukin Therapeutics) is a biopharmaceutical company develops next generation immunotherapies to treat immunological disorders. The company's lead drug candidate NL-201 is a combined IL-2 and IL-15 protein therapeutic used as an agonist in the treatment of cancer immunotherapy. Its propriety platform de novo – proteins enable to build custom protein therapeutics. Neoleukin Therapeutics serves in the therapeutic areas of rheumatoid arthritis, inflammatory bowel disease, asthma, multiple sclerosis, atopic dermatitis, and solid tumors. The company seeks to collaborate...
Add to Basket -
Product Insights
Net Present Value Model: NL-201
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model NL-201 Drug Details NL-201 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NL-201
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NL-201 Drug Details NL-201 is under development for the treatment of advanced solid tumors, renal...
-
Product Insights
Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms may include night sweats, fever and chills that come and go, itching, putting pressure on the windpipe (trachea) or other airways, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if cancer affects the brain. Treatment includes surgery,...
-
Product Insights
Graft Versus Host Disease (GVHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness, and weight loss. Treatment includes immunosuppressants. The GVHD pipeline market research report provides comprehensive information on the therapeutics under development for GVHD, complete with analysis by stage of development, drug target, mechanism...
-
Product Insights
Bone Marrow Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bone Marrow Transplant Rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. The Bone Marrow Transplant Rejection - drugs in development research report provides a comprehensive overview on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis...